The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Retrospective cohort study on the safety and efficacy of bevacizumab for metastatic colorectal cancer patients: The HGCSG0801 study—Efficacy of KRAS mutational status.
Susumu Sogabe
No relevant relationships to disclose
Satoshi Yuki
No relevant relationships to disclose
Hideyuki Hayashi
No relevant relationships to disclose
Hirohito Naruse
No relevant relationships to disclose
Michio Nakamura
No relevant relationships to disclose
Ichiro Iwanaga
No relevant relationships to disclose
Takashi Kato
No relevant relationships to disclose
Tomofumi Takagi
No relevant relationships to disclose
Hiroyuki Okuda
No relevant relationships to disclose
Yoshito Komatsu
No relevant relationships to disclose